These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 1909711

  • 21. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
    Richard K, Mann BJ, Qin A, Barry EM, Ernst RK, Vogel SN.
    Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
    [Abstract] [Full Text] [Related]

  • 22. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.
    Dreisbach VC, Cowley S, Elkins KL.
    Infect Immun; 2000 Apr; 68(4):1988-96. PubMed ID: 10722593
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis.
    Lin Y, Ritchea S, Logar A, Slight S, Messmer M, Rangel-Moreno J, Guglani L, Alcorn JF, Strawbridge H, Park SM, Onishi R, Nyugen N, Walter MJ, Pociask D, Randall TD, Gaffen SL, Iwakura Y, Kolls JK, Khader SA.
    Immunity; 2009 Nov 20; 31(5):799-810. PubMed ID: 19853481
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies.
    Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA.
    Infect Immun; 1992 Jan 20; 60(1):84-9. PubMed ID: 1729199
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Tularemia vaccines - an overview.
    McMurry JA, Moise L, Gregory SH, De Groot AS.
    Med Health R I; 2007 Oct 20; 90(10):311-4. PubMed ID: 18019188
    [Abstract] [Full Text] [Related]

  • 38. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection.
    Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP.
    Immunol Cell Biol; 2008 Oct 20; 86(6):515-22. PubMed ID: 18427567
    [Abstract] [Full Text] [Related]

  • 39. Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria.
    Ryden P, Twine S, Shen H, Harris G, Chen W, Sjostedt A, Conlan W.
    Mol Immunol; 2013 May 20; 54(1):58-67. PubMed ID: 23201853
    [Abstract] [Full Text] [Related]

  • 40. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis.
    Golovliov I, Ericsson M, Akerblom L, Sandström G, Tärnvik A, Sjöstedt A.
    Vaccine; 1995 Feb 20; 13(3):261-7. PubMed ID: 7631511
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.